Regardless of the molecular mechanism, the functional significance of stabilizing actin appears clear. Actin is a major consumer of ATP [19] and the observed stabilization of actin filaments therefore prevents the consumption of ATP, whilst retaining actin filaments and their polarity. This polarity retention may be important to allow growth using the existing cytoskeleton with minimal ATP consumption, if the post-starvation environment provides enough nutrients for growth.
Parkinson's disease-associated PINK1 and Parkin maintain mitochondrial health through promoting mitophagy, the autophagic removal of damaged mitochondria, in non-neuronal cells. Whether they do so in neurons has been controversial. A new study aims to resolve the controversy.
Bingwei Lu
Mitochondria play essential roles in many aspects of cellular physiology, from energy production and intermediary metabolism to apoptosis [1] . Proper mitochondrial function is particularly important for the health of neurons, as suggested by the prominent manifestation of neurological impairments in mitochondrial diseases [2] . Mitochondrial dysfunction has been observed in many of the age-related neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease (PD) [2] . However, the origin of the mitochondrial dysfunction in most of these diseases remains elusive. Pten-induced kinase 1 (PINK1) and Parkin, two genes linked to familial PD, have been implicated in mitochondrial quality control, specifically the promotion of mitochondrial degradation by autophagy -mitophagy. Many of the studies indicating a function for PINK1 and Parkin in mitophagy were carried out in cultured non-neuronal cells, but a new study published in the Journal of Cell Biology [3] now suggests that PINK1 and Parkin can indeed act in neuronal axons to remove damaged mitochondria.
PD is the most common movement disorder and the second most common neurodegenerative disease after Alzheimer's disease. It is characterized by rather selective degeneration of dopaminergic neurons in substantia nigra of the midbrain, although other brain regions can also be affected. The cause of degeneration of dopaminergic neurons is presumably diverse, with mitochondrial dysfunction, protein misfolding, oxidative stress, and endoplasmic reticulum stress having been implicated [4] . That mitochondrial dysfunction plays a causal role in PD pathogenesis is supported by the observations that mitochondrial toxins, such as MPTP and rotenone, can cause PD-like symptoms in humans and animal models [5] , and that mutations in PINK1, a mitochondria-targeted serine/threonine kinase, cause early onset familial PD [6] . Genetic studies in Drosophila first established that PINK1 and Parkin act in a common pathway to maintain mitochondrial health, with PINK1 acting upstream of Parkin [7] [8] [9] .
Work from the Youle laboratory offered a key clue on the mechanism of action of the PINK1-Parkin pathway in this process. They showed that Parkin, a normally cytosolic protein, is recruited in a PINK1-dependent manner to dysfunctional mitochondria, which are characterized by reduced membrane potential [10] . Parkin induces broad ubiquitination and degradation of mitochondrial outer membrane proteins [11] . The prevailing view is that these ubiquitinated proteins serve as an 'eat me' signal on damaged mitochondria that is recognized by ubiquitin-binding adaptor proteins, which recruit the autophagy machinery and induce mitophagy. This mitophagy model of PINK1-Parkin action is attractive for its simplicity and explanatory power, and the experimental system used (treatment of HeLa cells overexpressing YFP-Parkin with the mitochondrial toxin CCCP) has been widely adopted by investigators in the field. However, it remains to be seen whether Parkin-mediated mitophagy is essential for the maintenance of a healthy pool of mitochondria in neurons under steady-state conditions in intact animals.
A few studies carried out in cultured mammalian primary cortical neurons or in induced pluripotent stem cell (iPSC)-derived human dopaminergic neurons have generated conflicting results regarding the role of PINK1-Parkin in handling mitochondrial damage. An initial study failed to observe Parkin translocation and mitophagy in CCCP-treated mouse cortical neurons [12] , whereas later studies found that, under different culture conditions, Parkin translocation to damaged mitochondria can occur and that mitophagy can be observed in neuronal soma [13, 14] . To complicate things further, studies in iPSC-derived human dopaminergic neurons showed that mitochondrial damage failed to induce mitophagy, even when Parkin was overexpressed [15, 16] . Thus, whether neurons, especially the diseaserelevant dopaminergic neurons, undergo PINK1-Parkin-dependent mitophagy in response to mitochondrial damage remains unclear.
Previous studies of neuronal mitophagy used global application of the mitochondrial toxins CCCP, a chemical uncoupler, or valinomycin, a potassium ionophore, both of which trigger loss of mitochondrial membrane potential. In the new study [3] , Ashrafi et al. used two methods to induce localized damage to axonal mitochondria. In the first method, a genetically encoded photosensitizermitochondria-targeted KillerRed (mt-KR) -was employed. Light-induced activation of mt-KR causes reactive oxygen species (ROS)-mediated damage to mitochondria. In the second method, microfluidic local perfusion chambers were used to induce mitochondrial depolarization in axonal segments via perfusion of actinomycin A, an inhibitor of respiratory complex III and a less toxic compound than CCCP. The authors observed that axonal mitochondria damaged by mt-KR or actinomycin A colocalize with autophagosomes and lysosomes, suggesting that mitophagy is initiated in distal axons. This contrasts with findings from a previous study, which observed neuronal mitophagy primarily in the somatodendritic compartment, but this observation was made at much later time points after drug treatment than those used in the current study [13] .
To explore the mechanism of the observed mitophagy in their experimental settings, Ashrafi et al. [3] turned to the PINK1-Parkin pathway. A key step in the PINK1-Parkin-regulated mitophagy process is the recruitment of Parkin to damaged mitochondria. Although available antibodies have so far failed to detect recruitment of endogenous Parkin to mitochondria, the authors were able to observe Parkin recruitment to mt-KR-or actinomycin-damaged mitochondria by using low-level expression of a YFP-Parkin reporter. Furthermore, using cultured neurons derived from parkin -/-mice, they found that the recruitment of autophagosomes to damaged axonal mitochondria was abolished. Similarly, using cultured neurons derived from pink1 -/-rats, the authors showed that the recruitment of Parkin and autophagosomes to damaged axonal mitochondria is PINK1 dependent. Thus, the PINK1-Parkin pathway previously defined in flies appears to be operating in axons of mammalian neurons to promote mitophagy. The implication of this finding is immense. It suggests that axons, and possibly dendrites, are key subcellular sites of action of the PINK1-Parkin pathway, potentially reflecting the particularly high demand for energy production and calcium buffering by these sites. When the PINK1-Parkin pathway is impaired, damaged mitochondria at these sites may cause synaptic dysfunction, one of the earliest signs of neurodegeneration.
In addition to the questions it answered, many further questions are raised by this study. One of the key observations of this study is that Parkin is recruited to only a portion of the depolarized mitochondria and that even fewer mitochondria are engulfed by autophagosomes. This may reflect a stochastic onset of mitophagy caused by the presumably limited supply of PINK1, Parkin, or the autophagy machinery in neuronal axons. Alternatively, this may reflect functional heterogeneity of neuronal mitochondria and their differential responses to experimentally induced damage. Perhaps, after similar mt-KR-or actinomycin-inflicted insults, more robust mitochondria can be rescued by repair, whereas the 'old' or 'worn-out' mitochondria will be damaged beyond repair and subjected to autophagic removal. If this were the case, it would be exciting to test whether mitochondrial repair and biogenesis can also occur locally in axons. The conventional wisdom is that most mitochondrial biogenesis-related events occur in the soma, but this remains to be rigorously tested. Related to this point, previous studies in other experimental settings [17] have observed that mitochondria with low membrane potential preferentially undergo retrograde transport (Figure 1 ). These unhealthy mitochondria will presumably accumulate in the soma, where they may be repaired or removed [18] . Intriguingly, Ashrafi et al. [3] find that most of the damaged mitochondria that recruit autophagosomes are stationary. However, not all of these mitoautophagosomes fuse with lysosomes during the observation period, raising the possibility that some of them may eventually be returned to the soma via retrograde transport. This would reconcile with an earlier report of PINK1-Parkin-mediated mitophagy in neuronal soma observed at later time points [13] , and also be consistent with the earlier observation of mitochondria in moving autophagosomes [19] . It is even possible that the formation of the mitoautophagosomes in neuronal axons may indicate a traffic-redirection mechanism in which damaged mitochondria are dislodged from the microtubule motor-based mitochondria transport system and get connected to the autophagosome transport system. Further studies of the transport systems associated with damaged mitochondria will test this hypothesis. Finally, it will be important to test whether the PINK1-Parkindirected mitophagy pathway operates in vivo in neuronal axons, especially those of disease-susceptible dopaminergic neurons, in disease models or in aged normal animals. This is an urgent task considering that the PINK1-Parkin pathway is particularly important for the survival and function of these neurons, yet studies in iPSC-derived human dopaminergic neurons have so far failed to reveal Parkin-mediated mitophagy [16] , and in vivo studies in mice showed that dysfunctional and depolarized mitochondria in dopaminergic neurons are not removed by Parkin-mediated mitophagy [20] . Thus, the key mechanism of action of the PINK1-Parkin pathway in dopaminergic neurons remains a major unanswered question, the answer to which could have significant therapeutic implications. 
